WO2008096804A1 - ラタノプロスト含有点眼剤 - Google Patents

ラタノプロスト含有点眼剤 Download PDF

Info

Publication number
WO2008096804A1
WO2008096804A1 PCT/JP2008/052005 JP2008052005W WO2008096804A1 WO 2008096804 A1 WO2008096804 A1 WO 2008096804A1 JP 2008052005 W JP2008052005 W JP 2008052005W WO 2008096804 A1 WO2008096804 A1 WO 2008096804A1
Authority
WO
WIPO (PCT)
Prior art keywords
latanoprost
eye drop
drop preparation
prevented
plastic container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052005
Other languages
English (en)
French (fr)
Japanese (ja)
Other versions
WO2008096804A8 (ja
Inventor
Takahito Kimura
Joshu Watanabe
Minoru Kobayashi
Makoto Seki
Takao Shimatani
Chiharu Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teika Pharamaceutical Co Ltd
Original Assignee
Teika Pharamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teika Pharamaceutical Co Ltd filed Critical Teika Pharamaceutical Co Ltd
Priority to JP2008557147A priority Critical patent/JPWO2008096804A1/ja
Priority to EP08704514A priority patent/EP2123278B1/en
Priority to US12/526,349 priority patent/US20100120908A1/en
Publication of WO2008096804A1 publication Critical patent/WO2008096804A1/ja
Publication of WO2008096804A8 publication Critical patent/WO2008096804A8/ja
Anticipated expiration legal-status Critical
Priority to US13/922,837 priority patent/US20130281529A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PCT/JP2008/052005 2007-02-07 2008-02-07 ラタノプロスト含有点眼剤 Ceased WO2008096804A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008557147A JPWO2008096804A1 (ja) 2007-02-07 2008-02-07 ラタノプロスト含有点眼剤
EP08704514A EP2123278B1 (en) 2007-02-07 2008-02-07 Eye drop preparation comprising latanoprost
US12/526,349 US20100120908A1 (en) 2007-02-07 2008-02-07 Eye drop preparation comprising latanoprost
US13/922,837 US20130281529A1 (en) 2007-02-07 2013-06-20 Eye drop preparation comprising latanoprost

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2007028498 2007-02-07
JP2007-028498 2007-02-07
JP2007-166788 2007-06-25
JP2007166788 2007-06-25
JP2007245937 2007-09-21
JP2007-245937 2007-09-21
JP2007338661 2007-12-28
JP2007-338661 2007-12-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/922,837 Continuation US20130281529A1 (en) 2007-02-07 2013-06-20 Eye drop preparation comprising latanoprost

Publications (2)

Publication Number Publication Date
WO2008096804A1 true WO2008096804A1 (ja) 2008-08-14
WO2008096804A8 WO2008096804A8 (ja) 2009-04-02

Family

ID=39681708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052005 Ceased WO2008096804A1 (ja) 2007-02-07 2008-02-07 ラタノプロスト含有点眼剤

Country Status (4)

Country Link
US (2) US20100120908A1 (https=)
EP (1) EP2123278B1 (https=)
JP (2) JPWO2008096804A1 (https=)
WO (1) WO2008096804A1 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009040749A (ja) * 2007-08-10 2009-02-26 Kaken Pharmaceut Co Ltd ラタノプロスト点眼剤
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
WO2010075444A3 (en) * 2008-12-22 2010-11-04 Evoke Pharma, Inc. Nasal formulations of metoclopramide
JP2010275259A (ja) * 2009-05-29 2010-12-09 Toa Yakuhin Kk 均一、かつ安定なラタノプロスト点眼液剤組成物
WO2011001634A1 (en) * 2009-06-30 2011-01-06 Santen Pharmaceutical Co., Ltd. Method for improving bioavailability of latanoprost
WO2010130462A3 (de) * 2009-05-14 2011-01-27 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische zusammensetzung zur glaukombehandlung
WO2011027778A1 (ja) * 2009-09-01 2011-03-10 株式会社アールテック・ウエノ 高眼圧症および緑内障処置のための眼局所投与用組成物
WO2011034192A1 (ja) 2009-09-17 2011-03-24 千寿製薬株式会社 ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法
JP2011509237A (ja) * 2008-10-07 2011-03-24 株式会社アールテック・ウエノ 医薬組成物
JP2013513606A (ja) * 2009-12-09 2013-04-22 アラーガン インコーポレイテッド プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
JP2013535505A (ja) * 2010-08-11 2013-09-12 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドの安定な製剤
US11020361B2 (en) 2008-12-22 2021-06-01 Evoke Pharma, Inc. Nasal formulations of metoclopramide
JP2021176825A (ja) * 2020-05-08 2021-11-11 株式会社セラバリューズ クルクミン含有経口摂取用固形製剤
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
WO2022173043A1 (ja) * 2021-02-15 2022-08-18 参天製薬株式会社 ウルソデオキシコール酸またはその塩を含有する水性医薬組成物
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
RU2839141C1 (ru) * 2024-10-21 2025-04-28 Закрытое акционерное общество "Фармацевтическая фирма "ЛЕККО" Лекарственное средство на основе латанопроста в жидком виде и способ его получения

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US20120108672A1 (en) * 2009-06-25 2012-05-03 Hazuki Tsutsui Ophthalmic composition and method for prevention of cloudiness/precipitation
WO2011001951A1 (ja) * 2009-06-30 2011-01-06 ライオン株式会社 眼科用組成物
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
NZ630759A (en) * 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
MY178371A (en) * 2014-09-25 2020-10-09 Kowa Co Pharmaceutical preparation
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
CN118526450A (zh) * 2024-05-24 2024-08-23 兆科（广州）眼科药物有限公司 一种拉坦前列素眼用凝胶剂及其制备方法与用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2721414B2 (ja) 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
JPH11500122A (ja) 1994-12-22 1999-01-06 アルコン ラボラトリーズ，インコーポレイテッド 貯蔵安定性プロスタグランジン組成物
JP2001515502A (ja) * 1997-03-17 2001-09-18 ノバルティス アクチエンゲゼルシャフト 高眼圧を低下させるための組成物及び方法
JP2002161037A (ja) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd 点眼液
JP2002520368A (ja) 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド プロスタグランジン製品
JP2004182719A (ja) 2002-08-23 2004-07-02 Santen Pharmaceut Co Ltd ラタノプロストを有効成分とする安定な点眼液
WO2005044276A1 (ja) 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
JP2006503913A (ja) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物
WO2007015510A1 (ja) * 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
JP2007063265A (ja) 2005-08-02 2007-03-15 Santen Pharmaceut Co Ltd 熱的に不安定な薬物の分解抑制方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP2003206241A (ja) * 2002-01-11 2003-07-22 Teika Seiyaku Kk 眼科用剤
JP2004123729A (ja) * 2002-09-09 2004-04-22 Santen Pharmaceut Co Ltd ラタノプロストを有効成分とする澄明な点眼液
CA2707067C (en) * 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2721414B2 (ja) 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
JP3612178B2 (ja) 1988-09-06 2005-01-19 ファルマシア・アクチエボラーグ プロスタグランジン誘導体を含有する緑内障または眼圧亢進の局所治療のための眼科用組成物
JPH11500122A (ja) 1994-12-22 1999-01-06 アルコン ラボラトリーズ，インコーポレイテッド 貯蔵安定性プロスタグランジン組成物
JP2005015498A (ja) 1994-12-22 2005-01-20 Alcon Lab Inc 貯蔵安定性プロスタグランジン組成物
JP2001515502A (ja) * 1997-03-17 2001-09-18 ノバルティス アクチエンゲゼルシャフト 高眼圧を低下させるための組成物及び方法
JP2002520368A (ja) 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド プロスタグランジン製品
JP2002161037A (ja) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd 点眼液
JP2004182719A (ja) 2002-08-23 2004-07-02 Santen Pharmaceut Co Ltd ラタノプロストを有効成分とする安定な点眼液
JP2006503913A (ja) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物
WO2005044276A1 (ja) 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
WO2007015510A1 (ja) * 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
JP2007063265A (ja) 2005-08-02 2007-03-15 Santen Pharmaceut Co Ltd 熱的に不安定な薬物の分解抑制方法

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
JP2009040749A (ja) * 2007-08-10 2009-02-26 Kaken Pharmaceut Co Ltd ラタノプロスト点眼剤
JP2011509237A (ja) * 2008-10-07 2011-03-24 株式会社アールテック・ウエノ 医薬組成物
US12194008B2 (en) 2008-12-22 2025-01-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11813231B2 (en) 2008-12-22 2023-11-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11628150B2 (en) 2008-12-22 2023-04-18 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11020361B2 (en) 2008-12-22 2021-06-01 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US12194009B2 (en) 2008-12-22 2025-01-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010075444A3 (en) * 2008-12-22 2010-11-04 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US8334281B2 (en) 2008-12-22 2012-12-18 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010130462A3 (de) * 2009-05-14 2011-01-27 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische zusammensetzung zur glaukombehandlung
EP2429507B1 (de) 2009-05-14 2017-07-19 URSAPHARM Arzneimittel GmbH Phosphatfreie pharmazeutische zusammensetzung zur glaukombehandlung
JP2010275259A (ja) * 2009-05-29 2010-12-09 Toa Yakuhin Kk 均一、かつ安定なラタノプロスト点眼液剤組成物
JP2012532091A (ja) * 2009-06-30 2012-12-13 参天製薬株式会社 ラタノプロストのバイオアベイラビリティを向上させる方法
WO2011001634A1 (en) * 2009-06-30 2011-01-06 Santen Pharmaceutical Co., Ltd. Method for improving bioavailability of latanoprost
EA022390B1 (ru) * 2009-06-30 2015-12-30 Сантен Фармасьютикал Ко., Лтд. Способ улучшения биодоступности латанопроста
WO2011027778A1 (ja) * 2009-09-01 2011-03-10 株式会社アールテック・ウエノ 高眼圧症および緑内障処置のための眼局所投与用組成物
WO2011034192A1 (ja) 2009-09-17 2011-03-24 千寿製薬株式会社 ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法
EP2478906A4 (en) * 2009-09-17 2013-02-20 Senju Pharma Co AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN
JP2016056207A (ja) * 2009-12-09 2016-04-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
JP2013513606A (ja) * 2009-12-09 2013-04-22 アラーガン インコーポレイテッド プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
JP2013535505A (ja) * 2010-08-11 2013-09-12 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドの安定な製剤
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
US12377064B2 (en) 2016-12-15 2025-08-05 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
JP2021176825A (ja) * 2020-05-08 2021-11-11 株式会社セラバリューズ クルクミン含有経口摂取用固形製剤
JP7080504B2 (ja) 2020-05-08 2022-06-06 株式会社セラバリューズ クルクミン含有経口摂取用固形製剤
JP2022101629A (ja) * 2020-10-14 2022-07-06 参天製薬株式会社 安定な医薬組成物
JP7062846B1 (ja) * 2020-10-14 2022-05-06 参天製薬株式会社 安定な医薬組成物
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
WO2022173043A1 (ja) * 2021-02-15 2022-08-18 参天製薬株式会社 ウルソデオキシコール酸またはその塩を含有する水性医薬組成物
RU2839141C1 (ru) * 2024-10-21 2025-04-28 Закрытое акционерное общество "Фармацевтическая фирма "ЛЕККО" Лекарственное средство на основе латанопроста в жидком виде и способ его получения

Also Published As

Publication number Publication date
EP2123278A1 (en) 2009-11-25
WO2008096804A8 (ja) 2009-04-02
JPWO2008096804A1 (ja) 2010-05-27
US20100120908A1 (en) 2010-05-13
EP2123278A4 (en) 2010-04-21
US20130281529A1 (en) 2013-10-24
EP2123278B1 (en) 2013-01-09
JP2013189450A (ja) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2008096804A1 (ja) ラタノプロスト含有点眼剤
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
WO2010120693A3 (en) Methods and apparatus for overlaying content onto a common video stream
WO2009126960A3 (en) Multilayer fragrance encapsulation
WO2006127689A8 (en) Methods for managing release of one or more ingredients in an edible composition based on ratios of ingredients to encapsulating materials
WO2008103427A3 (en) Consumer food storage package with absorbent food pad
WO2008064259A3 (en) Solid dispersion composition comprising fluvastatin
WO2007124237A3 (en) Systems and methods for providing a thermoplastic product that includes packaging therefor
WO2009014116A1 (ja) ゼリー入りアルコール飲料及びその製造方法
EP2039370A4 (en) OPHTHALMIC COMPOSITIONS FOR SOFT CONTACT LENSES WITH TERPENOID
EP2305577A4 (en) Container with squeeze nozzle and lever
WO2008051450A3 (en) Composition comprising ionomer and polyamide
WO2007127354A3 (en) Homogeneous dispersions containing citrus pulp and applications thereof
ZA201009059B (en) Low amidine content polyvinylamine,compositions containing same and methods
EP1866752A4 (en) ADAPTIVE CONTENT PLATFORM AND APPLICATION INTEGRATION IN THE PLATFORM
WO2011061654A3 (en) Solidification matrix using a maleic-containing terpolymer binding agent
WO2005107501A3 (en) Article for inhibiting microbial growth
WO2009028674A1 (ja) ラタノプロスト含有水性医薬組成物
WO2008011433A3 (en) Styrenated terpene resin as well as methods of making and using the same
WO2009125937A3 (ko) 왁스-수지 상용화제, 및 상기 왁스-수지 상용화제를 함유하는 왁스-수지 분산액와 그의 제조방법
WO2009095141A3 (en) Silicon dioxide dispersion
WO2008055614A3 (en) Flowers
WO2007098924A3 (de) Zusammensetzung umfassend ein mittel zum stabilisieren von wirkstoffen im trinkwasser und eine brausemischung, verfahren zu deren herstellung und deren verwendung
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
ZA200706104B (en) Rooibos extract with increased aspalathin content, process for the preparation of such a rooibos extract, and cosmetic agent containing such a rooibos extract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704514

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008557147

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12526349

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008704514

Country of ref document: EP